Articles By Rob Wright, Chief Editor 2011-2021
-
![01_FromThe]( "What JPM 2017 Revealed To Me")
What JPM 2017 Revealed To Me2/1/2017As I walked into a breakout session on at JPM, I couldn’t help but overhear people discussing the latest negative news to hit the biopharma industry.
-
![05_Feature_CSLBehring]( "The Secrets To CSL Limited's Incredible Revenue Growth")
The Secrets To CSL Limited's Incredible Revenue Growth2/1/2017CSL Limited’s CEO Paul Perreault gives us a behind-the-scenes look at how the company increased revenue by 33% while also increasing R&D by 73% and capital investment by 83%.
-
![Leadership Lessons From Chris Ruisi — Author Of Step Up And Play Big]( "Leadership Lessons From Chris Ruisi — Author Of \"Step Up And Play Big\"")
Leadership Lessons From Chris Ruisi — Author Of "Step Up And Play Big"1/30/2017We’ve all probably encountered the frustrations related to flight delays and cancellations. I recently experienced the latter while on my way to the 35th Annual J. P. Morgan Healthcare Conference (commonly referred to as JPM) in San Francisco. Although, one positive did come out of my unplanned delay — it afforded me the opportunity to get through a leadership book I had been meaning to read, Step Up And Play Big by Chris Ruisi.
-
![Despite Delays, JPM 2017 Still Pays Off For Me]( "Despite Delays, JPM 2017 Still Pays Off For Me")
Despite Delays, JPM 2017 Still Pays Off For Me1/19/2017For the second year in a row my travel plans to the biopharmaceutical industry’s yearly kickoff event — the 35th Annual J. P. Morgan Healthcare Conference in San Francisco — were disrupted by weather. And though I once again arrived a day late, there was still plenty to keep me busy during JPM.
-
![01_From_the_Editor]( "What You Need To Know About Being Ready To Join A Board")
What You Need To Know About Being Ready To Join A Board1/1/2017Chief Editor Rob Wright talks with a few pharma industry icons about what to expect when seeking a board appointment.
-
How Boehringer Ingelheim Is Redefining Its R&D Strategy1/1/2017
In November 2015, Boehringer Ingelheim (BI) announced its new five-year R&D strategy, which included a commitment to invest $11 billion. Clive Wood, Ph.D., SVP of discovery research at BI, sat down with Life Science Leader to explain how the company is redefining its R&D strategy in order to maximize internal potential and expand research “for and beyond therapeutic area borders.”
-
![07_FeatureTakeda]( "Inside Takeda Oncology's Patient Advocacy Program")
Inside Takeda Oncology's Patient Advocacy Program12/29/2016So how does a lawyer become head of patient advocacy at one of the largest biopharma companies in the world? In Liz Lewis’s case, it started at the Washington, DC-based law firm, Epstein, Becker and Green where she represented healthcare and life sciences companies and served as cochair for the firm’s pharmaceutical practice group.
-
![04_Feature_CEOTrendsetters]( "What 13 Life Science Trendsetters Expect For 2017 And Beyond")
What 13 Life Science Trendsetters Expect For 2017 And Beyond12/1/2016The sharing of this knowledge is meant not merely to provide you wisdom, but hopefully inspire insight.
-
![01_FromThe]( "And The Magic 8 Ball Says...")
And The Magic 8 Ball Says...12/1/2016Chief Editor Rob Wright talks about the art of making predictions as compared to educated deduction. For this issue, we steer toward the latter.
Rob Wright
Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL